A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.
EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.
As SAR439859 and RG6171 move into pivotal testing, the Serd approach to treating one form of breast cancer generates renewed interest.
Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.
G1 Therapeutics fast-tracks what it says is the first CDK4/6 inhibitor aimed at reducing chemotherapy-induced myelosuppression.